- Home
- MCGA vs ALLO Comparison
MCGA vs ALLO Comparison
Compare MCGA & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCGA | ALLO |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.6M | 252.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | MCGA | ALLO |
|---|---|---|
| Price | $10.20 | $2.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.27 |
| AVG Volume (30 Days) | 226.4K | ★ 4.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.09 | $0.86 |
| 52 Week High | $10.83 | $2.80 |
Technical Indicators
Market Signals| Indicator | MCGA | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 63.75 | 65.34 |
| Support Level | $10.10 | $1.01 |
| Resistance Level | $10.22 | N/A |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 70.00 | 79.03 |
Price Performance
Historical ComparisonAbout MCGA Yorkville Acquisition Corp. Class A Ordinary Share
Yorkville Acquisition Corp is a blank check company.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.